A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18 MCG of Tiotropium inhalation capsules administered by Handihaler® once-daily plus PRN Albuterol (Salbutamol) vs. placebo plus PRN Albuterol (Salbutamol) in Chronic Obstructive Pulmonary Disease subjects naive to maintenance therapy. - N/A

SCS Boehringer Ingelheim Comm.V0 个研究点目标入组 436 人开始时间: 2007年6月4日最近更新: 2012年3月19日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 436

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. All subjects must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial, which includes medication washout and restrictions.
•2. All subjects must have a diagnosis of COPD according to GOLD guideline criteria: post-bronchodilator FEV1/FVC ratio < 70% (visit 1).
•3. Subjects must be GOLD Stage II and have a post-bronchodilator FEV1 >50% and < 80% of predicted normal (visit 1).
•4. Subjects must be male or female, 40-80 years of age.
•5. Subjects must be current or ex-smokers with a smoking history of >10 pack years.
•6. Subjects must have a Medical Research Council (MRC) dyspnea score > 2.
•7. Subjects must be able to demonstrate compliance with the HandiHaler® and an albuterol (salbutamol) MDI during the screening period.
•8. Subjects must be able to demonstrate compliance with the activity monitor during the screening period.
•9. Subjects must be able to perform acceptable PFTs and follow study procedures.
•10. Subjects must be able to perform an Exercise Stress Test.
•11. Subjects must be able to demonstrate a stabilized smoking status at least 1 month prior to visit 1.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Subjects who have been treated with maintenance medications for chronic respiratory disease (e.g. long acting ß-agonists, inhaled anticholinergics, inhaled or systemic corticosteroids, theophylline, leukotriene receptor antagonists) within six months prior to screening.
•2. Subjects with significant diseases other than COPD. A significant disease is defined as a disease or condition, which, in the opinion of the investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject’s ability to participate in the study.
•3. Subjects who have ever had a diagnosis of asthma, cystic fibrosis, bronchiectasis, interstitial lung disease, or pulmonary thromboembolic disease documented by a physician.
•4. Subjects with a history of pulmonary resection.
•5. Subjects with a history of thoracotomy for other reasons should be evaluated as per Exclusion criteria 2.
•6. Subjects on chronic systemic corticosteroids.
•7. Subjects with any upper and/or lower respiratory tract infection or COPD exacerbation in the 6 weeks prior to the initial visit 1 or during the screening period prior to visit 3.
•8. Subjects who exacerbate in the 6 weeks prior to screening can be re-screened after recovery from the exacerbation.
•9. Subjects who exacerbate during the screening period can be re-screened 6 weeks following recovery from the exacerbation.
•10. Subjects whose activity is significantly limited by non-pulmonary disease (i.e., arthritis). Subjects with a recent (past 6 months) myocardial infarction, any unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy during the last year; or who have been hospitalized for cardiac failure during the past year.
•11. Subjects who are known to have clinically significant laboratory and/or electrocardiogram abnormalities in the judgment of the Investigator.
•12. Subjects who have any contraindication to exercise or have abnormal exercise stress test results based on criteria established by the ACC/AHA 1997 and/or the ATS/ACCP 2003 and/or thought to be of clinical significance in the judgment of the investigator or his medical designee
•13. Subjects with a malignancy and who are currently undergoing radiation therapy or have had chemotherapy within 5 years.
•14. Subjects who are pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception for at least three months prior to screening and for the duration of the trial.
•15. Subjects who are currently participating or have recently participated in another trial with investigational drug within 30 days or 6 half-lives of the investigational agent (whichever is greater) at the start of the study or who are currently participating in another interventional study.
•16. Subjects with a known hypersensitivity to anticholinergic drugs, lactose or any other component of the inhalation capsule or metered dose aerosol delivery systems.
•17. Subjects with a known nickel-cutaneous hypersensitivity (component of the activity monitor).
•18. Subjects who are currently or have ever been in a pulmonary rehabilitation program.
•19. Subjects who are currently or that have been in a cardiac rehabilitation program within 6 months prior to visit 1.
•20. Subjects with a history of significant alcohol or drug abuse.
•21. Subjects with known active tuberculosis
•22. Subjects with known narrow-angle glaucoma.
•23. Subjects with moderate

研究者

发起方

SCS Boehringer Ingelheim Comm.V

相似试验

进行中（未招募）

不适用

A 24 week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 18 MCG of Tiotropium inhalation capsules administered by Handihaler® once-daily plus PRN Albuterol (Salbutamol) vs. placebo plus PRN Albuterol (Salbutamol) in Chronic Obstructive Pulmonary Disease subjects naive to maintenance therapy. - N/AChronic Obstructive Pulmonary Disease

EUCTR2006-006276-38-PTBoehringer-Ingelheim436

进行中（未招募）

不适用

EUCTR2006-006276-38-NLBoehringer-Ingelheim436

招募中

不适用

Effect of medicinal herb aqueous extract on height growth in childre

CTRI/2022/10/046687Korea Medicine Research Institute

进行中（未招募）

1 期

EUCTR2006-006276-38-GBBoehringer Ingelheim Limited436

进行中（未招募）

不适用

EUCTR2006-006276-38-GRBoehringer Ingelheim Hellas AE436